BioSpace News Archive

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Steve Williamson as Chief Commercial Officer.

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that Ms. Ye (Sally) Wang was appointed, effective November 6, 2020, as Chairwoman of the Board of Director

MRx0518 demonstrates upregulation of key immune biomarkers associated with anti-cancer activity in neoadjuvant monotherapy setting Addition of new tumor type cohorts to ongoing Part B of Phase I/II combination trial with pembrolizumab, following 42% disease control rate (DCR) in completed Part A Company to host virtual KOL event to review data on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET)

Test will be deployable to support risk-based management of COVID-19, Influenza and other severe respiratory disease

AGEN1181 : New clinical responses and intratumoral Treg depletion AGEN 1777 ( TIGIT ) is Fc enhanced for optimized immune performance & broader benefit AGEN2373 (anti-CD137) : Clinical benefit with no liver toxicity Allogeneic iNKTs : Potent tumor cell killing and tumor microenvironment regulation VISION : Proprietary platform for response prediction and optimal combos Zalifrelimab (anti-CTLA-4) : 1 CR, 2 PRs, and 52% benefit in PD-1 refractory tumors

Eureka Therapeutics, Inc. , a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that Randy Schekman, Ph.D., has been appointed to its Scientific Advisory Board. Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine for his ground-breaking work on cell membrane vesicle trafficking. He is currently a Professor in the Department of Molecular and Ce

-- XmAb20717 was generally well-tolerated; 19% objective response rate (ORR) observed across cohorts at the recommended dose level -- -- Early clinical activity, including prostate-specific antigen (PSA) reductions in patients with advanced prostate cancer, support initiation of new Phase 1b study in 2021--

Halberd Corp. reported the filing of a Covid-19 provisional patent on an enhanced nasal spray.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced a series of recently issued patents for its Phase 2b/3 clinical-stage lead product candidate, Validive (clonidine HCl mucobuccal tablet). These patents, including U.S. Patent No. 10,675,271, provide claims covering

- Katherine Vega Stultz appointed as chief operating officer - Philip P. Gutry appointed as chief business officer and head of finance & investor relations - Executive hires follow appointment of Dr. Josh Lehrer as chief executive officer